GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (WBO:TKD) » Definitions » Gross Profit

Takeda Pharmaceutical Co (WBO:TKD) Gross Profit : €18,426 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Takeda Pharmaceutical Co Gross Profit?

Takeda Pharmaceutical Co's gross profit for the three months ended in Dec. 2023 was €4,660 Mil. Takeda Pharmaceutical Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €18,426 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Takeda Pharmaceutical Co's gross profit for the three months ended in Dec. 2023 was €4,660 Mil. Takeda Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was €7,077 Mil. Therefore, Takeda Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2023 was 65.85%.

Takeda Pharmaceutical Co had a gross margin of 65.85% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Takeda Pharmaceutical Co was 71.99%. The lowest was 66.89%. And the median was 69.05%.


Takeda Pharmaceutical Co Gross Profit Historical Data

The historical data trend for Takeda Pharmaceutical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Gross Profit Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,509.93 18,504.12 17,028.14 18,853.86 19,449.48

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,321.77 4,516.71 4,815.54 4,433.28 4,660.14

Competitive Comparison of Takeda Pharmaceutical Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Gross Profit falls into.



Takeda Pharmaceutical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Takeda Pharmaceutical Co's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=28142.626 - 8693.145
=19,449

Takeda Pharmaceutical Co's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=7077.003 - 2416.866
=4,660

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €18,426 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Takeda Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=4,660 / 7077.003
=65.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Takeda Pharmaceutical Co  (WBO:TKD) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Takeda Pharmaceutical Co had a gross margin of 65.85% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Takeda Pharmaceutical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (WBO:TKD) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (WBO:TKD) Headlines

No Headlines